Liver tumors in animals trigger clinical hold for BioMarin gene therapy — highlighting a recurring concern
Hours after the FDA wrapped its marathon listening session on the safety risks of gene therapy, BioMarin offered a reminder of why the advisory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
